PCI Biotech Holding ASA

FRA:4QG (Norway)  
€ 0.11 (+2.28%) Dec 20
At Loss
P/B:
1.52
Market Cap:
€ 4.12M ($ 4.28M)
Enterprise V:
€ 1.57M ($ 1.63M)
Volume:
-
Avg Vol (2M):
20.00
Trade In:

Business Description

Description
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.
Name Current Vs Industry Vs History
Cash-To-Debt 64.29
Equity-to-Asset 0.85
Debt-to-Equity 0.02
Debt-to-EBITDA -0.04
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 39.52
9-Day RSI 41.43
14-Day RSI 42.63
6-1 Month Momentum % -33.78
12-1 Month Momentum % -38.15

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.86
Quick Ratio 6.86
Cash Ratio 5.67

Dividend & Buy Back

Name Current Vs Industry Vs History
Shareholder Yield % 0.96
Name Current Vs Industry Vs History
ROE % -29.82
ROA % -26.23
ROIC % -281.21
ROC (Joel Greenblatt) % -904.96
ROCE % -31.03

Financials (Next Earnings Date:2025-02-27)

FRA:4QG's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

PCI Biotech Holding ASA Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €)
EPS (TTM) (€) -0.027
Beta 1.47
Volatility % 59.35
14-Day RSI 42.63
14-Day ATR (€) 0.00515
20-Day SMA (€) 0.11901
12-1 Month Momentum % -38.15
52-Week Range (€) 0.102 - 0.23
Shares Outstanding (Mil) 37.33

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

PCI Biotech Holding ASA Filings

Filing Date Document Date Form
No Filing Data

PCI Biotech Holding ASA Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

PCI Biotech Holding ASA Frequently Asked Questions

What is PCI Biotech Holding ASA(FRA:4QG)'s stock price today?
The current price of FRA:4QG is €0.11. The 52 week high of FRA:4QG is €0.23 and 52 week low is €0.10.
When is next earnings date of PCI Biotech Holding ASA(FRA:4QG)?
The next earnings date of PCI Biotech Holding ASA(FRA:4QG) is 2025-02-27.
Does PCI Biotech Holding ASA(FRA:4QG) pay dividends? If so, how much?
PCI Biotech Holding ASA(FRA:4QG) does not pay dividend.

Press Release

Subject Date
No Press Release